Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WENDY apixaban pharmacokinetics before and after Roux-en-Y gastric bypass
NL-OMON59528Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apixaban in venous thromboembolism (VTE), sponsored by Amsterdam University Medical Center. Primary endpoint: Area under the curve of anti-Xa levels. Planned start May 2025; status: not yet recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON59528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59528.